Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - Oct 23, 2023 - P1 | N=28 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: May 2024 ➔ May 2025 | Trial primary completion date: May 2023 ➔ May 2025
Metastases • Trial completion date • Trial primary completion date • Melanoma • Oncology • Prostate Cancer • Solid Tumor
|